Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-01-03

Clinical Trial Update: Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy, safety, and tolerability of oral ubrogepant for acute treatment of migraine has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ubrogepant (ubrogepant)

Snippet

Sponsor: Allergan | Conditions: Migraine, With or Without Aura | Phase 3 | Status: COMPLETED | Results posted: 2019-01-03